Whether different definitions of metabolic syndrome (MetS) are differently associated with colorectal adenocarcinoma (CA) by anatomical location is unclear. A population-based cohort study, the Cohort of Norway (CONOR) Study, was conducted in Norway from 1995 to 2010. Anthropometric measurements, blood samples, and lifestyle data were collected at recruitment. CAs were identified through linkage to the Norwegian Cancer Register. A composite index of MetS as defined by the International Diabetes Federation (IDF) or/and the National Cholesterol Education Program's Adult Treatment Panel III (ATP III) and single components of MetS, including anthropometric factors, blood pressure, lipids, triglycerides, and glucose, were analyzed. Cox proportional hazards regression was performed to estimate hazard ratios and 95% confidence intervals. Significant associations between single MetS components and CA, except for reduced high-density lipoprotein cholesterol and nonfasting glucose levels, were observed. MetS defined by 2 criteria separately showed a similar association with CA in general, and MetS defined by both the IDF and ATP III showed consistent results. Stronger associations were observed in the proximal colon among men (IDF: hazard ratio (HR) = 1.51, 95% confidence interval (CI): 1.24, 1.84; ATP III: HR = 1.40, 95% CI: 1.15, 1.70) and in the rectum among women (IDF: HR = 1.42, 95% CI: 1.07, 1.89; ATP III: HR = 1.43, 95% CI: 1.08, 1.90).
Metabolic syndrome, as assessed according to current international definitions by the key components central obesity, dyslipidemia, elevated blood pressure, and abnormal glucose metabolism, is associated with colorectal cancer in accumulating studies (1, 2) . The definition of metabolic syndrome varies, however, which may indicate that the associations might be dissimilar. The 3 widely used definitions for metabolic syndrome are: 1) the new International Diabetes Federation (IDF) definition (3, 4) ; 2) the National Cholesterol Education Program's Adult Treatment Panel III (ATP III) definition (5) ; and 3) the World Health Organization (WHO) clinical criteria for metabolic syndrome (5) . Although several previous studies have demonstrated a positive association between metabolic syndrome and colorectal cancer risk (2, (6) (7) (8) , only 1 has investigated metabolic syndrome defined by different criteria in this context (7) . Single components vary slightly in the different definitions of metabolic syndrome. However, the extent to which single components account for such an association by different definitions remains unclear (7, (9) (10) (11) (12) . Furthermore, some studies found that metabolic syndrome was associated with colorectal cancer only in men (9, 13) ; others demonstrated the opposite (14) . Because of the distinct sex-specific incidence pattern of colorectal adenocarcinoma in the proximal colon, distal colon, and rectum, previous studies that did not evaluate risk by anatomical location may have confounded the sex-specific association with metabolic syndrome and/or its single components. Most previous studies have analyzed the colon and rectum separately but have omitted the distinction between the proximal colon and the distal colon, which warrants further investigation.
In the current study, we examined the association of metabolic syndrome, based on different definitions, with risk of colorectal cancer in the Cohort of Norway (CONOR) Study, a large, prospective population-based cohort study in Norway. Since adenocarcinoma is the main histological type of neoplasm in the colon and rectum (more than 90%), the study focuses on colorectal adenocarcinoma.
METHODS

Study population
Design and data collection in the CONOR Study have been described in detail elsewhere (15) . In summary, CONOR is a research collaboration between the Norwegian Institute of Public Health and the universities of Bergen, Oslo, Tromsø, and Trondheim (Norwegian University of Science and Technology). Merging data from 10 epidemiologic studies covering the period 1995-2010, CONOR was established as a national database to study risk factors for a wide range of diseases. In a recent profile of the CONOR cohort, Naess et al. (15) described the locations of these 10 sites in Norway and the websites of each participating study.
Letters of invitation for the original studies were mailed to potential participants approximately 2 weeks before the time of the baseline appointment for each study. In total, 309,832 persons were invited to participate in the individual studies, and 180,553 did so. Participants underwent a standardized physical examination, and a nonfasting blood sample was drawn at the screening. After (nonmutual) exclusion of participants who were included in 2 rounds of surveys (n = 7,310), those with prevalent cancer (n = 6,075), those with missing anthropometric data (n = 21,234), and those missing data on daily smoking status (n = 1,551), 143,477 persons remained for the final analysis.
Identification of colorectal cancer cases
Using the unique 11-digit national identity number assigned to all Norwegian citizens, the CONOR cohort was followed up through linkage to the Norwegian Cancer Register and the Statistics Norway database. Colorectal cancer was identified from the Norwegian Cancer Register according to the International Classification of Diseases, Seventh Revision (ICD-7). The ICD-7 codes for colorectal cancer (by anatomical location) included codes 1530 and 1531 for the proximal colon (the appendix, cecum, ascending colon, hepatic flexure, transverse colon, and splenic flexure); codes 1532, 1533, and 1534 for the distal colon (the descending colon and sigmoid colon); and code 1540 for the rectum. Each CONOR participant was considered at risk from the point of enrollment in the cohort to the date of colorectal cancer diagnosis, death, censoring (e.g., loss to follow-up, emigration, diagnosis of other malignancies), or the end of follow-up (December 31, 2010), whichever came first.
The Regional Committee for Medical and Health Research Ethics, Central Norway, approved the current study. All of the individual studies included in the CONOR database were approved by their respective ethics committees. All participants signed an informed consent form.
Assessment of metabolic syndrome components
Whole blood (5-7 mL) was collected from the participants, and serum was separated by centrifuging at the screening site. All laboratory assessments in CONOR were performed at the Department of Clinical Chemistry, Oslo University Hospital (Ullevål, Norway), except those for the Second Health Survey of Nord-Trøndelag (HUNT II)), for which the analyses were performed at the Department of Clinical Chemistry, Levanger Hospital (Levanger, Norway). Nonfasting serum total cholesterol and high-density lipoprotein (HDL) cholesterol, glucose, and triglyceride concentrations were measured directly using an enzymatic method (Boehringer 148393, Boehringer Mannheim, Mannheim, Germany; from 2000 onwards, Hitachi 917 Chemistry Analyzer, Roche Diagnostics, Basel, Switzerland). Acceptable stability of the laboratory analyses over time in the population surveys has been reported (16) .
Blood pressure and heart rate were measured in all of the CONOR studies at dedicated research clinics. Three measurements were recorded, and the mean value was calculated from the second and third measurements (17) . The stability of the blood pressure measures has been evaluated as acceptable (18) . Waist circumference was measured at the umbilicus to the nearest centimeter with the subject standing and breathing normally. Hip circumference was measured as the maximum circumference around the buttocks. Waist:hip ratio was calculated from measurements of waist circumference versus hip circumference. Body weight (in kilograms, to 1 decimal place) and height (in centimeters, to 1 decimal place) were measured with the participant wearing light clothing without shoes. The measurements were manually recorded until the year 2000; after that, an electronic height and weight scale was used. Body mass index was calculated as body weight (kilograms) divided by the square of height (meters squared). Information on the use of lipid-lowering or antihypertensive medication was collected through self-reports.
Definition of the metabolic syndrome
Based on the data available in CONOR, 2 definitions of the metabolic syndrome, the IDF definition and the ATP III definition, were analyzed and compared (Table 1) (3, 5) . The WHO criteria included components of impaired glucose tolerance, impaired fasting glucose, or insulin resistance (5), for which data were not available or not computable in this study. Thus, analysis of the overall definition of metabolic syndrome based on the WHO criteria was omitted, but accessible single components of the WHO definition were analyzed, including raised waist:hip ratio (men: ≥0.90, women: ≥0.85), reduced HDL cholesterol level (men: <0.9 mmol/L, women: <1.0 mmol/L), hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg), and raised fasting glucose level (≥6.1 mmol/L).
According to the IDF definition (3, 4) , a person with metabolic syndrome has central obesity (increased waist circumference based on European standards (≥94 cm for men, ≥80 cm for women, or body mass index ≥30)) plus any 2 of the following 4 factors: 1) raised triglyceride level (≥1.7 mmol/L) or use of lipid-lowering medication; 2) reduced HDL cholesterol level (men: <1.03 mmol/L, women: <1.29 mmol/L); 3) raised blood pressure (systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or use of antihypertensive medication); and 4) raised fasting plasma glucose level (≥5.6 mmol/L) ( Table 1) . Raised fasting glucose level was defined by plasma glucose concentration and a diagnosis of diabetes. Since nonfasting blood samples were collected (time since the last meal ranged from 2 hours to 8 hours), these results might not reflect actual fasting glucose level.
According to the ATP III criteria (5), a person with metabolic syndrome has 3 or more of the following single components: 1) central obesity (men: >102 cm, women: >88 cm); 2) hypertension (systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or use of antihypertensive medication); 3) hypertriglyceridemia (≥1.7 mmol/L); 4) reduced HDL cholesterol level (men: <1.03 mmol/L, women: <1.29 mmol/L); and 5) elevated fasting glucose level (≥5.6 mmol/L) ( Table 1) .
Statistical analysis
Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals. Associations between single metabolic syndrome components, the overall metabolic syndrome definition, and use of IDF and ATP III criteria and colorectal cancer were computed by anatomical location. All of the variables were categorical.
Each single component of the metabolic syndrome was analyzed on the basis of a crude model adjusting for age and sex and a multivariable model adjusting for potential confounders as well. Since the results based on the crude and multivariable models were not materially different, only the results of the multivariable analyses were reported. Confounders were chosen on the basis of previous etiological studies on colorectal cancer, together with stepwise selection approaches. The following covariables were included in the final model: age (<50, 50-60, or ≥60 years), education (none/primary school/ secondary school, high school, or university), daily smoking status (never/seldom, current), alcohol consumption (never/ seldom, about once a month, 2-3 times per month, about once a week, or several times per week), and physical activity (0, <1, 1-2, or ≥3 hours/week). Further analyses of anthropometric measurements were stratified by sex.
In sensitivity analyses, we excluded the first 2 years of follow-up in order to decrease the potential bias of reverse causality. Age was categorized into more refined groups (<40 years, 40-44 years, 45-49 years, etc.) and analyzed in the multivariate model for the additional analysis. Since the results were not materially changed, we only show them in Web Table 1 (available at http://aje.oxfordjournals.org/). For missing values, we treated the variables in 2 different ways: We either 1) deleted participants with missing values or 2) treated persons with missing values as a single category. Since the final results did not change materially, we chose either approach depending on the percentage of missing values in the relevant variables. Therefore, in the final analysis, missing values for smoking status were deleted (n = 1,551; 0.89%) and missing values for other variables were kept as a separate category. The proportional hazards assumption for the Cox regression model was tested on the basis of Schoenfeld residuals. None of the variables violated the proportional hazards assumption, except for age group, which was treated as a stratification factor in the final model. A 2-sided test with a significance level (α) of 0.05 was chosen. All analyses were performed using SAS 9.3 for Windows (SAS Institute, Inc., Cary, North Carolina) and Stata 13.0 (StataCorp LP, College Station, Texas). 
RESULTS
Population
With an average of 11.3 years of follow-up, 2,044 colorectal adenocarcinomas were identified in the total cohort (Table 2) . With metabolic syndrome defined by the IDF (n = 43,775), ATP III (n = 40,234), or both (n = 31,500), 927, 823, and 695 colorectal adenocarcinomas, respectively, were identified. Men had a higher incidence of adenocarcinoma in the distal colon (54.8%) and rectum (61.8%), while women had a higher incidence in the proximal colon (51.9%). The mean age in proximal colon cases (65.8 years) was slightly higher than that in cases in the distal colon and rectum (63.4 years and 63.5 years, respectively). Smoking and alcohol consumption (several times per week) seemed to be more frequent among rectal adenocarcinoma cases. Comorbidity (diabetes, cardiovascular diseases, and asthma) was more prevalent in proximal adenocarcinoma cases (Table 2) . Single components of the metabolic syndrome
The risk of colorectal adenocarcinoma was increased by approximately 20% with both the European (men: ≥94 cm, women: ≥80 cm) and US (men: ≥102 cm, women: ≥88 cm) definitions of central obesity using waist circumference ( Table 3 ). The risk was mainly increased in the colon and not in the rectum. When central obesity was indirectly defined by body mass index ≥30, the risk became attenuated (16%). Increased waist:hip ratio showed results similar to those of waist circumference.
There was a marginally increased risk of colorectal adenocarcinoma (12%) with a higher triglyceride level (≥1.7 mmol/ L vs. <1.7 mmol/L) ( Table 3 ). However, lipid-lowering drugs seemed to potentially protect against colorectal adenocarcinoma, especially in the distal colon (hazard ratio (HR) = 0.63, 95% confidence interval (CI): 0.42, 0.95). Reduced HDL cholesterol level did not show a significant association with colorectal adenocarcinoma based on 2 categorizations.
Raised blood pressure combined with the use of antihypertensive medication was associated with 18% and 13% increased risks of colorectal adenocarcinoma using the IDF/ATP III definition of hypertension and the WHO definition of hypertension, respectively (Table 3) . Raised glucose levels were not associated with colorectal adenocarcinoma. However, self-reported diabetes increased the risk of colorectal adenocarcinoma by 36%, mainly in the proximal colon (49%).
Comparison of the IDF and ATP III definitions of metabolic syndrome
Both the IDF and ATP III definitions of metabolic syndrome showed positive associations with colorectal adenocarcinoma overall, regardless of sex (Table 4 ). The IDF definition displayed slightly higher hazard ratios than the ATP III definition with regard to colorectal adenocarcinoma in general (IDF: HR = 1.24, 95% CI: 1.13, 1.36; ATP III: HR = 1.17, 95% CI: 1.07, 1.28). Both definitions were consistently associated with adenocarcinoma in the proximal colon, especially in men (IDF: HR = 1.51, 95% CI: 1.24, 1.84; ATP III: HR = 1.40, 95% CI: 1.15, 1.70), and with rectal adenocarcinoma in women (IDF: HR = 1.42, 95% CI: 1.07, 1.89; ATP III: HR = 1.43, 95% CI: 1.08, 1.90); these associations were not indicated by the single components of metabolic syndrome.
When assessing persons classified as having metabolic syndrome by both definitions (IDF and ATP III), we also found an increased risk of colorectal adenocarcinoma overall (HR = 1.26, 95% CI: 1.14, 1.40) ( Table 5 ). Having metabolic syndrome by both definitions was associated with an increased risk of adenocarcinoma in the proximal colon, especially in men (men: HR = 1.63, 95% CI: 1.30, 2.03; women: HR = 1.24, 95% CI: 1.00, 1.54). Similar to results for the separate metabolic syndrome definitions (Table 4) , the increased risk of adenocarcinoma in the rectum among women was still apparent (HR = 1.52, 95% CI: 1.13, 2.06).
We also investigated the role central obesity played in the associations between different metabolic syndrome definitions and colorectal adenocarcinoma risk, as compared with noncentral obesity ( Web Figures 1 and 2 ; see also Web Tables 2 and 3). The results showed that central obesity alone was not associated with an increased risk of colorectal adenocarcinoma, while metabolic syndrome with central obesity was (Web Figures 1 and 2) . The association was quite consistent with the aforementioned results given in Tables 4 and 5 . However, we also observed 2 exceptional results in men: First, central obesity was negatively associated with rectal adenocarcinoma based on the IDF criteria (Web Figure 1) . Second, central obesity alone seemed to be associated with a 60% increased risk of adenocarcinoma in the distal colon (Web Figure 2) when using the ATP III definition. Since the definition of central obesity is different in the IDF and ATP III criteria, these results may need to be interpreted further on the basis of the specific definitions.
DISCUSSION
In the current study, we found that the metabolic syndrome as a composite index defined by the IDF, ATP III, or both, as well as single components of metabolic syndrome (e.g., central obesity, raised triglyceride level, and raised blood pressure), were associated with an increased risk of colorectal adenocarcinoma in general. Metabolic syndrome with central obesity contributes to the development of colorectal adenocarcinoma. The association with metabolic syndrome as a composite index was more prominent for adenocarcinoma of the proximal colon in men and rectal adenocarcinoma in women.
The strengths of this study include the large, prospectively enrolled cohort, with a high number of colorectal adenocarcinoma cases. Moreover, the anthropometric variables were measured objectively by means of standardized protocols at baseline. Furthermore, blood samples were collected and lipid levels were measured using standard procedures. A weakness of the study is that the blood samples were not collected after fasting, so information on fasting glucose level was not available. However, data on prevalent diabetes were collected. In addition, data on the use of lipid-lowering or antihypertensive drugs were collected through self-reports, which might not have produced complete information on the medications taken. Another weakness was the lack of detailed information on dietary/nutrient intake, which may have resulted in residual confounding.
In the current study, single components of the metabolic syndrome, including central obesity, raised triglyceride level, and raised blood pressure, showed positive associations with colorectal adenocarcinoma, especially in the proximal colon, although some components displayed a stronger relationship. In the Women's Health Initiative, a positive association of the metabolic syndrome with colorectal cancer was largely accounted for by serum glucose level and systolic blood pressure (8) . In the Physicians' Health Study (male participants with 494 colorectal cancer cases), being overweight and having diabetes were associated with increased risks of colorectal cancer, but elevated blood pressure and hypercholesterolemia were not (6) . In the European Prospective Investigation into Cancer and Nutrition, abnormal glucose metabolism and/or central obesity were regarded as the main contributors to metabolic syndrome that were associated with an increased risk of colorectal cancer (7) . Recent studies have demonstrated that central obesity may primarily account for this association (8, 11, 19) . This is consistent with our results. More interestingly, our results showed that central obesity alone was associated with an increased risk of adenocarcinoma in the distal colon among men based on the ATP III criteria but a decreased risk of rectal adenocarcinoma based on the IDF definition. Because the definition of central obesity is more stringent in the ATP III criteria, this indicates that central obesity might be an independent risk factor for distal colon adenocarcinoma. Furthermore, people who have central obesity but no metabolic syndrome according to the IDF definition are probably obese but metabolically healthy individuals. This indicates that "metabolically healthy obesity" might be associated with a reduced risk of rectal adenocarcinoma in men. The underlying mechanism, however, is unclear.
The other single components of the metabolic syndrome are more or less related to central obesity or a consequence of central obesity (20, 21) . Waist circumference, a surrogate measure of visceral adipose tissue, is the commonly used index for central obesity. Visceral adipose tissue is physiologically more active than subcutaneous adipose tissue, and it generates hormones and cytokines with inflammatory, metabolic, and direct carcinogenic potential, which may directly or indirectly increase colorectal cancer risk (22) . Current evidence suggests that obesity acts as a risk factor for colorectal cancer through several mechanisms, including chronic low-grade inflammation, hyperinsulinemia, and alterations in insulin-like growth factor and adipokine concentrations (22, 23) . Specific molecules derived from visceral adipose tissue, including adiponectin, leptin, and resistin, are able to establish a positive feedback loop, thus increasing the proinflammatory and insulin-resistant state and promoting tumorigenesis (22, 24) . Metabolic syndrome may be a marker of a physiological milieu of growth that encourages tumor initiation, promotion, and progression.
Previous studies have found that the metabolic syndrome is associated with colorectal cancer in men but not in women, but the results are largely inconsistent (7-9, 13, 25, 26) . The present study found significant associations for both sexes but also sex-specific associations (e.g., a stronger association for rectal adenocarcinoma in women), which is consistent with a recent meta-analysis (19, 27) . Another study found that only high levels of metabolic factors confer an increased risk (10) . However, in the present study, a lower waist circumference (based on the European definition) conferred a more evident association. A negative association between the use of lipid-lowering medication and distal colon adenocarcinoma was observed. This was actually consistent with previous studies regarding the potential negative association of lipid-lowering drugs (e.g., statins) with cancer (28) .
Few studies have compared the risks of colorectal adenocarcinoma by anatomical location using the single components of the metabolic syndrome or a composite index of the metabolic syndrome as defined by the IDF or ATP III, or the metabolic syndrome as defined by both. Our findings regarding a significant association of metabolic syndrome with proximal colon cancer were consistent with previous studies (29, 30) . Furthermore, in the current study we observed a significant association between the metabolic syndrome as a composite index and rectal adenocarcinoma in women, an association which was actually not obvious for single components. The distinct pattern of colorectal adenocarcinoma incidence by anatomical location (e.g., female predominance in the proximal colon, male predominance in the distal colon and rectum, and older age-specific incidence in the proximal colon) may indicate etiological differences. The proximal colon might be more influenced by internal disorders of metabolic factors, especially sex hormones, which are different in obese women and men. A hypothesis raised by McMichael and Potter in the 1980s (31) considered that sex hormones may alter bile acid synthesis, which possibly acts in a more concentrated manner on the proximal colon where fecal bile acids are reabsorbed. Experimental studies have also demonstrated a remarkable difference in the expression pattern of genes according to the anatomical location of colorectal cancer, which may help to interpret the stronger association between metabolic syndrome and adenocarcinoma of the proximal colon in the current study (32) . By contrast, adenocarcinoma in the distal colon and rectum seemed to be affected more evidently by factors involved in energy balance, such as obesity, physical activity, diet, and gut microbiota. In a recent meta-analysis, Robsahm et al. (33) found that physical activity was differently associated with cancer in the colon and the rectum, although no differences between the colonic subsites were observed. In summary, in this study the metabolic syndrome and its components were associated with an increased risk of colorectal adenocarcinoma, especially in the proximal colon among men and in the rectum among women. Central obesity may play a pivotal role connected with other components. Understanding the links of metabolic syndrome and its components to carcinogenesis has major clinical significance and may have profound health benefits for prevention of colorectal cancer, which represents an important cause of mortality and morbidity in our society.
